HK1091815A1 - [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia - Google Patents

[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Info

Publication number: HK1091815A1
Authority: HK; Hong Kong
Prior art keywords: naphthyridin; schizophrenia; ones; treatment; related compounds
Prior art date: 2003-08-22

Application number

HK06112251.3A

Other languages

English (en)

Inventor

Jerry Clark

Jamie Davis

Favor D David

Fay L Lorraine

Lloyd Franklin

Kevin Heneger

Douglas Johnson

Brian Nichelson

Ligong Ou

Joseph Thomas Repine

Michael Walters

Andrew David White

Zhijian Zhu

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-22

Filing date

2006-11-08

Publication date

2007-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1091815(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-11-08 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2007-01-26 Publication of HK1091815A1 publication Critical patent/HK1091815A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HK06112251.3A 2003-08-22 2006-11-08 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia HK1091815A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49737003P	2003-08-22	2003-08-22
PCT/IB2004/002665 WO2005019215A1 (en)	2003-08-22	2004-08-13	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number	Publication Date
HK1091815A1 true HK1091815A1 (en)	2007-01-26

Family

ID=34216117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK06112251.3A HK1091815A1 (en)	2003-08-22	2006-11-08	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Country Status (36)

Country	Link
US (3)	US7160888B2 (es)
EP (1)	EP1660497A1 (es)
JP (1)	JP4034811B2 (es)
KR (2)	KR100765668B1 (es)
CN (1)	CN100422181C (es)
AP (1)	AP2006003525A0 (es)
AR (1)	AR045386A1 (es)
AU (1)	AU2004266191B2 (es)
BR (1)	BRPI0413860A (es)
CA (1)	CA2538915C (es)
CR (2)	CR8254A (es)
CU (1)	CU23464B7 (es)
EA (1)	EA009645B1 (es)
EC (1)	ECSP066391A (es)
GE (1)	GEP20084447B (es)
GT (1)	GT200500007A (es)
HK (1)	HK1091815A1 (es)
HN (1)	HN2004000319A (es)
IL (1)	IL173439A0 (es)
IS (1)	IS8267A (es)
MA (1)	MA28003A1 (es)
ME (1)	MEP45308A (es)
MX (1)	MXPA06002070A (es)
MY (1)	MY140693A (es)
NL (1)	NL1026892C2 (es)
NO (1)	NO20060324L (es)
NZ (1)	NZ545078A (es)
OA (1)	OA13238A (es)
PA (1)	PA8609701A1 (es)
PE (1)	PE20051039A1 (es)
RS (1)	RS20060129A (es)
TN (1)	TNSN06063A1 (es)
TW (1)	TWI298327B (es)
UA (1)	UA82541C2 (es)
WO (1)	WO2005019215A1 (es)
ZA (1)	ZA200601526B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904723D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
WO2003007956A1 (en) *	2001-07-20	2003-01-30	Psychogenics, Inc.	Treatment for attention-deficit hyperactivity disorder
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA06013941A (es)	2004-06-08	2007-12-10	Neurosearch Sweden Ab	Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
US7851629B2 (en)	2004-06-08	2010-12-14	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
NZ552411A (en) *	2004-06-08	2010-04-30	Nsab Af Neurosearch Sweden Ab	New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
KR101319235B1 (ko)	2004-10-13	2013-10-16	아이백스 인터내셔널 게엠베하	4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정
FR2877005A1 (fr) *	2004-10-22	2006-04-28	Bioprojet Soc Civ Ile	Nouveaux derives d'arylpiperazine
EP1846411A4 (en)	2005-01-25	2010-08-04	Glaxo Group Ltd	ANTIBACTERIAL ACTIVE SUBSTANCES
WO2006090273A2 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006103559A1 (en) *	2005-04-01	2006-10-05	Warner-Lambert Company Llc	Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
AU2006231917B2 (en) *	2005-04-08	2011-07-28	Pfizer Products Inc.	Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors
TWI320783B (en) *	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
JP4315393B2 (ja) *	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物
TWI329641B (en)	2005-08-31	2010-09-01	Otsuka Pharma Co Ltd	(benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
PT1940839E (pt)	2005-10-07	2013-10-10	Exelixis Inc	Inibidores de piridopirimidinona pi3k alfa
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007052104A2 (en) *	2005-10-31	2007-05-10	Pfizer Products Inc.	Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
US7935706B2 (en)	2006-02-23	2011-05-03	Shionogi & Co., Ltd.	Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2007116265A1 (en) *	2006-03-31	2007-10-18	Pfizer Products Inc.	Process for making a tetrahydro-pyridoazepin-8-one compound
MX2008014450A (es)	2006-05-18	2009-03-09	Mannkind Corp	Inhibidores de cinasa intracelular.
CA2663401C (en) *	2006-09-15	2011-07-12	Pfizer Products Inc.	Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
US20100093738A1 (en) *	2006-10-06	2010-04-15	Basf Se	Fungicidal Compounds and Fungicidal Compositions
JP4540700B2 (ja) *	2006-10-13	2010-09-08	大塚製薬株式会社	医薬
WO2008047883A1 (en) *	2006-10-13	2008-04-24	Otsuka Pharmaceutical Co., Ltd.	Piperazine-substituted benzothiophenes for treatment of mental disorders
WO2008084324A1 (en) *	2007-01-04	2008-07-17	Pfizer Products Inc.	Naphthyridinone compound
JP4785881B2 (ja) *	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CL2008001002A1 (es)	2007-04-11	2008-10-17	Actelion Pharmaceuticals Ltd	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
WO2008144764A1 (en) *	2007-05-21	2008-11-27	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
PE20090759A1 (es) *	2007-05-30	2009-07-20	Wyeth Corp	Derivados heteroarilo de benzodioxanos heterociclo-fusionados antidepresivos
US7928111B2 (en) *	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
PL2245028T3 (pl)	2007-12-18	2012-07-31	Actelion Pharmaceuticals Ltd	Pochodne 5-aminocyklilometyloksazolidyn-2-onu
JP2011529090A (ja)	2008-07-28	2011-12-01	江蘇国華投資有限公司	アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
CA2731800C (en)	2008-07-31	2018-03-20	Senomyx, Inc.	Processes and intermediates for making sweet taste enhancers
JP4955835B2 (ja)	2008-12-12	2012-06-20	アクテリオンファーマシューティカルズリミテッド	５−アミノ−２−（１−ヒドロキシ−エチル）−テトラヒドロピラン誘導体
WO2010085570A1 (en) *	2009-01-23	2010-07-29	Takeda Pharmaceutical Company Limited	Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
CN106045936A (zh) *	2009-02-26	2016-10-26	雷维瓦药品公司	芳基哌嗪衍生物、含有该衍生物的组合物及其制药用途
AU2010266040B2 (en)	2009-06-25	2015-01-15	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds
EP4124616A1 (en)	2009-06-25	2023-02-01	Alkermes Pharma Ireland Limited	Heterocyclic compounds for the treatment of neurological and psychological disorders
US8536328B2 (en)	2010-05-04	2013-09-17	Alkermes Pharma Ireland Limited	Process for synthesizing oxidized lactam compounds
US8592427B2 (en)	2010-06-24	2013-11-26	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en)	2010-07-02	2015-10-13	The University Of North Carolina At Chapel Hill	Functionally selective ligands of dopamine D2 receptors
BR112013013790A2 (pt)	2010-12-17	2016-09-13	Hoffmann La Roche	compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
MX358344B (es)	2011-03-18	2018-08-15	Alkermes Pharma Ireland Ltd	Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
JO3227B1 (ar) *	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
EP2787997A4 (en)	2011-12-08	2015-05-27	Ivax Int Gmbh	HYDROBROMIDE SALT OF PRIDOPIDINE
JP5952912B2 (ja)	2011-12-15	2016-07-13	アルカーメスファーマアイルランドリミテッド	二級アミン化合物のプロドラッグ
WO2013142198A1 (en)	2012-03-19	2013-09-26	Alkermes Pharma Ireland Limited	Pharmaaceutical compositions comprising fatty acid esters
WO2013142205A1 (en)	2012-03-19	2013-09-26	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
US9993556B2 (en)	2012-03-19	2018-06-12	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty glycerol esters
JP6177875B2 (ja)	2012-04-04	2017-08-09	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｔｅｒｎａｔｉｏｎａｌＧｍｂＨ	併用療法のための医薬組成物
US9951088B2 (en) *	2012-05-09	2018-04-24	Sunovion Pharmaceuticals Inc.	D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
EP2897592B1 (en)	2012-09-19	2020-02-19	Alkermes Pharma Ireland Limited	Pharmaceutical compositions having improved storage stability
RU2688233C2 (ru)	2014-03-20	2019-05-21	Алкермес Фарма Айэленд Лимитед	Препараты арипипразола, имеющие повышенные скорости впрыска
CN104785295B (zh) *	2015-03-18	2018-03-06	杭州创培信息科技有限公司	一种高选择性多巴胺铂炭催化剂的制备方法
EP3317278B1 (en)	2015-07-01	2021-04-14	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
US10874672B2 (en)	2015-12-10	2020-12-29	Ptc Therapeutics, Inc.	Methods for treating Huntington's disease
CN106242934A (zh) *	2016-07-26	2016-12-21	云南民族大学	一种酮的β‑位C‑H键乙酰氧化合成方法
KR20200033249A (ko)	2017-06-05	2020-03-27	피티씨 테라퓨틱스, 인크.	헌팅턴병 치료 화합물
CA3067592A1 (en)	2017-06-28	2019-01-03	Ptc Therapeutics, Inc.	Methods for treating huntington's disease
CN111182898B (zh)	2017-06-28	2024-04-16	Ptc医疗公司	用于治疗亨廷顿氏病的方法
WO2019023278A1 (en)	2017-07-25	2019-01-31	Crinetics Pharmaceuticals, Inc.	MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN112423754A (zh)	2018-03-05	2021-02-26	奥克梅斯制药爱尔兰有限公司	阿立哌唑的给药策略
AU2019232437A1 (en)	2018-03-07	2020-10-08	Bayer Aktiengesellschaft	Identification and use of ERK5 inhibitors
CA3094703A1 (en)	2018-03-27	2019-10-03	Ptc Therapeutics, Inc.	Compounds for treating huntington's disease
KR20210038845A (ko)	2018-06-27	2021-04-08	피티씨 테라퓨틱스, 인크.	헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020005882A1 (en)	2018-06-27	2020-01-02	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
SG11202012674PA (en)	2018-06-27	2021-01-28	Ptc Therapeutics Inc	Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814344B1 (en)	2018-08-07	2024-07-24	Firmenich Incorporated	5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
UA127629C2 (uk) *	2018-08-13	2023-11-08	Ф. Хоффманн-Ля Рош Аг	Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en)	2019-03-05	2022-10-18	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
AU2020328025A1 (en)	2019-08-14	2022-03-03	Incyte Corporation	Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2021048242A1 (en)	2019-09-12	2021-03-18	F. Hoffmann-La Roche Ag	4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
WO2021072232A1 (en)	2019-10-11	2021-04-15	Incyte Corporation	Bicyclic amines as cdk2 inhibitors
CN114634479B (zh) *	2020-12-16	2025-02-07	北京盈科瑞创新药物研究有限公司	一种派嗪衍生物、其制备方法及应用
US20240217977A1 (en) *	2021-03-31	2024-07-04	Blueprint Medicines Corporation	Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
WO2023178035A1 (en)	2022-03-14	2023-09-21	Slap Pharmaceuticals Llc	Multicyclic compounds
EP4501926A1 (en) *	2022-03-30	2025-02-05	Vigonvita Life Sciences Co., Ltd.	N-substituted quinolinone compound, preparation method therefor and use thereof
CN114805081B (zh) *	2022-05-20	2024-09-24	都创(上海)医药开发有限公司	一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5649361A (en)	1979-09-28	1981-05-02	Otsuka Pharmaceut Co Ltd	Carbostyril derivative
JPH07165720A (ja) *	1988-10-31	1995-06-27	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
WO1990006303A1 (en)	1988-12-02	1990-06-14	Pfizer Inc.	Arylpiperidine derivatives
DE69021645T2 (de)	1989-05-19	1996-02-22	Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.	N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5350747A (en)	1989-07-07	1994-09-27	Pfizer Inc	Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) *	1989-07-07	1991-01-24	Pfizer Inc.	Heteroaryl piperazine antipsychotic agents
US5032598A (en)	1989-12-08	1991-07-16	Merck & Co., Inc.	Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
MX9201991A (es) *	1991-05-02	1992-11-01	Jonh Wyeth & Brother Limited	Derivados de piperazina y procedimiento para su preparacion.
NZ240863A (en)	1991-09-11	1995-04-27	Mcneilab Inc	Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5206366A (en)	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
CZ284157B6 (cs)	1992-12-17	1998-08-12	Pfizer Inc.	Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
JP2781661B2 (ja)	1992-12-17	1998-07-30	フアイザー・インコーポレイテツド	Ｃｒｆアンタゴニストとしての置換ピラゾール
DK0674641T3 (da)	1992-12-17	1999-09-27	Pfizer	Pyrrolopyrimidiner som CRF-antagonister
TW336932B (en)	1992-12-17	1998-07-21	Pfizer	Amino-substituted pyrazoles
FR2699918B1 (fr)	1992-12-30	1995-03-17	Pf Medicament	Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) *	1994-01-21	1995-09-26	Otsuka Pharmaceut Co Ltd	３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr)	1995-03-02	1996-09-06	Pf Medicament	Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2987484B2 (ja) *	1995-03-16	1999-12-06	大塚製薬株式会社	カルボスチリル誘導体の製造方法
JP2900130B2 (ja) *	1995-03-16	1999-06-02	大塚製薬株式会社	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU6517196A (en)	1995-07-13	1997-02-10	Knoll Aktiengesellschaft	Piperazine derivatives as therapeutic agents
WO1997014419A1 (en)	1995-10-20	1997-04-24	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja)	1996-03-08	1997-09-16	Nippon Shinyaku Co Ltd	医薬
US5912256A (en)	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
FR2761071B1 (fr)	1997-03-20	1999-12-03	Synthelabo	Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr)	1997-10-16	2000-03-10	Pf Medicament	Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de)	1997-10-24	1999-04-29	Basf Ag	3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en)	1998-05-01	2001-07-31	Benz Research And Development Corporation	Intraocular lens and haptics made of a copolymer
WO2001046177A1 (en)	1999-12-20	2001-06-28	Eli Lilly And Company	Benzofuran derivatives
DE10041574A1 (de)	2000-08-24	2002-03-07	Merck Patent Gmbh	Chromenonderivate
WO2002048105A2 (en)	2000-11-16	2002-06-20	Wyeth	Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en)	2001-01-22	2001-03-07	Smithkline Beecham Plc	Compounds
AR032641A1 (es)	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
ATE312094T1 (de)	2001-06-29	2005-12-15	Lundbeck & Co As H	Neue heteroarylderivate, deren herstellung und verwendung
GB0227240D0 (en)	2002-11-21	2002-12-31	Glaxo Group Ltd	Compounds
TW200507841A (en)	2003-03-27	2005-03-01	Glaxo Group Ltd	Antibacterial agents
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active IP Right Cessation
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en active Application Filing
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active IP Right Cessation
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-11-08 HK HK06112251.3A patent/HK1091815A1/xx not_active IP Right Cessation
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20051039A1 (es)	2005-12-12
HN2004000319A (es)	2010-06-09
IS8267A (is)	2006-01-26
EP1660497A1 (en)	2006-05-31
GEP20084447B (en)	2008-08-10
NL1026892C2 (nl)	2005-11-21
CR8254A (es)	2006-10-17
RS20060129A (en)	2008-06-05
IL173439A0 (en)	2006-06-11
US7160888B2 (en)	2007-01-09
UA82541C2 (uk)	2008-04-25
CN100422181C (zh)	2008-10-01
TW200524938A (en)	2005-08-01
US20060287309A1 (en)	2006-12-21
CU23464B7 (es)	2009-12-17
GT200500007A (es)	2005-10-24
MXPA06002070A (es)	2006-05-19
NZ545078A (en)	2009-09-25
AR045386A1 (es)	2005-10-26
US20060287310A1 (en)	2006-12-21
TWI298327B (en)	2008-07-01
MA28003A1 (fr)	2006-07-03
ECSP066391A (es)	2006-08-30
WO2005019215A1 (en)	2005-03-03
CN1839134A (zh)	2006-09-27
NO20060324L (no)	2006-05-18
AU2004266191A1 (en)	2005-03-03
CA2538915A1 (en)	2005-03-03
KR100765668B1 (ko)	2007-10-10
OA13238A (en)	2006-12-13
MEP45308A (en)	2011-02-10
KR20070053364A (ko)	2007-05-23
CR9834A (es)	2008-04-21
AP2006003525A0 (en)	2006-02-28
MY140693A (en)	2010-01-15
PA8609701A1 (es)	2005-05-24
TNSN06063A1 (en)	2007-10-03
NL1026892A1 (nl)	2005-02-28
JP2007503386A (ja)	2007-02-22
ZA200601526B (en)	2007-04-25
CA2538915C (en)	2010-06-15
US20050043309A1 (en)	2005-02-24
EA200600294A1 (ru)	2006-08-25
KR20060071404A (ko)	2006-06-26
BRPI0413860A (pt)	2006-10-24
EA009645B1 (ru)	2008-02-28
JP4034811B2 (ja)	2008-01-16
KR100801794B1 (ko)	2008-02-05
AU2004266191B2 (en)	2009-11-26

Publication	Publication Date	Title
HK1091815A1 (en)	2007-01-26	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
HK1098737A1 (en)	2007-07-27	Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane
IL160884A0 (en)	2004-08-31	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2002364300A8 (en)	2003-07-15	Polymer derivatives for the treatment of metals
AU2003233010A8 (en)	2003-12-19	Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
GB0512558D0 (en)	2005-07-27	Microorganisms for well treatment
IL159344A0 (en)	2004-06-01	Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HUS2200036I1 (hu)	2022-08-28	Dihidroimidazolonok alkalmazása kutyák kezelésére
IL178899A0 (en)	2007-05-15	[3.2.0] heterocyclic compounds and methods of using the same
HK1087103A1 (en)	2006-10-06	Anilinopyrazole derivatives useful for the treatment of diabetes
PT1678185E (pt)	2009-01-13	Compostos 2,3-di-hidro-6-nitroimidazo[2,1-b]oxazole para o tratamento da tuberculose
AP2004002997A0 (en)	2004-03-31	Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
AU2003279442A8 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
GB0329874D0 (en)	2004-01-28	Compounds useful for the treatment of diseases
AP2005003336A0 (en)	2005-06-30	Combination for the treatment of ADHD
PL377464A1 (pl)	2006-02-06	Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
EP1551388A4 (en)	2009-07-15	COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
EP1461030A4 (en)	2005-06-01	AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
PL375564A1 (en)	2005-11-28	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
PT1698338E (pt)	2008-06-03	S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
IL162770A0 (en)	2005-11-20	Process for the preparation methylsteroids of 7
HK1080369A1 (zh)	2006-04-28	用於治療多發性骨髓瘤的埃博霉素衍生物
AU2003240174A8 (en)	2003-12-22	Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB2413797B (en)	2006-02-01	Microorganisms for well treatment
AU2003288724A1 (en)	2004-06-03	Clothing for partial protection of the body against biological agents

Legal Events

Date	Code	Title	Description
2013-03-08	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20120813